Summary of BeiGene Conference Call Company Overview - **Company**: BeiGene - **Industry**: Biotechnology, specifically focused on oncology Key Points and Arguments - **Market Position**: BeiGene is a leading player in the Chinese biotechnology industry, with strong global R&D, production, and commercialization capabilities. The year 2025 is pivotal, with expectations of profitability driven by the expansion of the BTK inhibitor, Zanubrutinib, in overseas markets. Revenue growth is projected at 21%, reaching $6.7 billion by 2027, with profits exceeding $800 million [3][4][29]. - **Product Pipeline**: BeiGene has a comprehensive pipeline in oncology, particularly in hematological malignancies, covering treatment scenarios from initial to relapsed and refractory stages with BTK inhibitors, BCL-2 inhibitors, and BTK-C degradation agents [4][5]. - **Zanubrutinib Performance**: Zanubrutinib has outperformed ibrutinib in head-to-head clinical trials, becoming the preferred therapy for C11 indications. It is expected to generate $2.6 billion in total revenue by 2024, with $2 billion from the U.S. market, marking a year-on-year doubling [4][15][17]. - **BCL-2 Inhibitor Development**: BeiGene is advancing its BCL-2 inhibitor in clinical trials, aiming to challenge existing competitors with fixed therapy approaches. A Phase III trial for chronic lymphocytic leukemia (CLL) is expected to complete enrollment in 2025, with a U.S. market launch anticipated by 2027 [4][18]. - **PD-1 Drug Commercialization**: The PD-1 drug, BaiZeAn, has been approved for 14 indications, with 13 covered by insurance in China. The domestic market is nearing saturation, while overseas markets are expected to contribute $500 million to $1 billion in growth, with peak sales potentially reaching $1 billion [4][23]. - **Breast Cancer Focus**: BeiGene is focusing on CDK4 inhibitors in breast cancer to address toxicity and resistance issues associated with existing CDK46 inhibitors. Early data shows promise, with positive proof of concept (POC) data expected in the first half of 2025 [4][24]. - **Risks**: Key risks include market competition for Zanubrutinib, price reduction risks from the U.S. IRA Act, uncertainties surrounding early clinical products, and potential impacts from biopharmaceutical procurement and insurance policies [4][30]. Additional Important Content - **Stock Performance**: From 2019 to 2021, BeiGene's stock price surged post-product launches. However, from 2022 to 2023, the stock faced pressure due to market conditions. Positive data releases for Zanubrutinib have significantly boosted stock performance [6]. - **Commercialization Team**: BeiGene has a global clinical team of 3,000 and a commercialization team of over 500 in the U.S. and Europe, enabling efficient multi-center clinical trials and substantial sales of nearly $2 billion in molecular drugs [9]. - **Future Growth Projections**: Revenue is expected to grow to $5 billion in 2025, $6 billion in 2026, and $6.7 billion in 2027, with a projected net profit exceeding $800 million by 2027 [29]. - **Valuation Estimates**: Based on management guidance, BeiGene's market value is estimated to reach $30 billion, driven by peak sales of its key products [28]. - **Emerging Competitors**: Several companies are developing BCL-2 targeted drugs, with BeiGene positioned in the leading tier, expecting to read out Phase III data in 2026 [19]. This summary encapsulates the critical insights from the conference call, highlighting BeiGene's strategic positioning, product pipeline, market dynamics, and potential risks.

Core Viewpoint - The article discusses the challenges of weight management and the phenomenon of weight regain after dieting, emphasizing the need for innovative solutions in the weight loss industry to combat this issue [1][2][6]. Group 1: Weight Management Initiatives - The National Health Commission of China has launched a three-year "Weight Management Year" initiative aimed at reducing weight and controlling chronic diseases [1]. - The concept of "metabolic memory" explains why individuals often regain weight after losing it, as the body tends to remember previous weight levels [2][6]. Group 2: Current Market Dynamics - The weight loss market is seeing significant sales, with drugs like semaglutide generating annual revenues of $28.3 billion [3]. - Major pharmaceutical companies, including Novo Nordisk and Eli Lilly, are focusing on developing new mechanisms and improving existing products to address muscle loss and weight regain during weight loss [2][10]. Group 3: Challenges in Weight Loss - Many weight loss methods lead to muscle loss, which can decrease the basal metabolic rate and exacerbate weight regain after stopping treatment [10]. - A study published in the Journal of the American Medical Association indicated that participants who stopped taking the weight loss drug tirzepatide regained an average of 14% of their lost weight within a year [8]. Group 4: Innovative Solutions and Research - Companies are exploring new drug targets and combination therapies to enhance weight loss while preserving muscle mass [10][11]. - The UK company NodThera is investigating an anti-inflammatory approach to weight loss, which has attracted interest from major players like Novo Nordisk [11]. Group 5: Long-term Weight Management Strategies - Experts recommend sustainable lifestyle changes, including balanced diets and regular exercise, as more effective long-term strategies for weight management compared to quick fixes [12][13]. - A comprehensive approach to weight management may involve a treatment cycle lasting over 20 months, focusing on identifying causes of obesity and designing personalized weight loss strategies [12].

2025 年 3 月 10 日 招银国际环球市场 | 睿智投资 | 行业研究 中国医药 预期药品集采政策优化，期待"创新药目录"落地 MSCI 中国医疗指数 2025 年初至今累计上涨 12.9%，跑输 MSCI 中国指数 7.6%。 受益于国内药品价格政策优化、国内宏观环境改善以及海外降息预期，医药行业有 望在 2025 年继续迎来估值修复。丙类医保目录年内即将落地，创新药将获得更好 的支付环境。医疗设备招标加速复苏，将推动国产医疗设备企业盈利复苏。 估值表 | | | | 市值 | 目标价 | 上行/ | P/E (x) | | P/B (x) | | ROE (%) | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 公司名称 | 股份代码 | 评级 | (百万美元) | | | | (LC) 下行空间 FY25E FY26E FY25E FY26E FY25E FY26E | | | | | | 百济神州 | ONC US | 买入 | 27,422.2 | 359.47 | 40% | 209 ...

宏 观 研 究 2025.03.10 每 周 经 济 动 态 近期美股市场下跌原因探析 方 正 证 券 研 究 所 证 券 研 究 报 告 《10 月美国 CPI 同比料在低基数下反弹》 2024.11.11 《基建实物工作量同比降幅收窄，地产销售延 续改善——量化经济指数周报-20241103》 2024.11.05 《美国大选投票日观察指南》2024.11.03 金晗 登记编号：S1220525030005 燕翔 登记编号：S1220525030001 相 关 研 究 《特朗普交易或有止盈风险，美联储料暂停降 息进程》2024.11.17 《建材价格延续回升指向建筑需求仍在改善— —量化经济指数周报-20241117》2024.11.17 2025 年 2 月中旬以来美股三大指数出现快速调整，截至 3 月 9 日收盘，标 普 500 指数相较于 2 月中旬的高点已下跌 6.1%，纳斯达克指数下跌 9.3%， 道琼斯指数下跌 4.1%。分行业看，美股可选消费、通讯服务、信息技术行 业领跌。我们认为，近期美股市场下跌的主要原因有以下三点：美国 AI 垄 断格局被打破、美国经济增长动力减弱、特朗普关税政策引发担 ...

Core Viewpoint - JD Health's 2024 annual performance announcement marks a new value benchmark for China's internet healthcare industry, showcasing strong revenue and profit growth driven by digital technology and new health consumption trends [1][2]. Revenue and Profit Performance - In 2024, JD Health reported total revenue of RMB 58.2 billion and a non-IFRS net profit of RMB 4.79 billion, both exceeding market expectations [2]. Reshaping Channel Efficiency - Health consumption has become a significant trend, with the government emphasizing the need for diverse service supply in health, elderly care, and other sectors. JD Health has restructured supply chain efficiency through a "self-operated + platform + instant retail" model, enhancing health consumption scenarios and expanding service reach [2]. Online Drug Sales Growth - The online drug purchasing mindset is maturing, with e-commerce channels becoming a core growth driver in the outpatient drug retail market. In 2024, China's pharmaceutical retail market reached RMB 501.9 billion, with e-commerce drug sales at RMB 64.5 billion, growing by 4.6% year-on-year, outpacing physical pharmacies [3]. Strengthening Partnerships with Pharmaceutical Companies - JD Health has enhanced its self-operated advantages and deepened collaborations with global pharmaceutical companies, facilitating the online launch of nearly 30 new specialty drugs in 2024 [3]. Instant Retail Expansion - JD Health is making strides in instant retail, particularly with its "online drug purchase with medical insurance account payment" service, which is now available in nearly 20 cities and connects over 3,000 medical insurance designated pharmacies, covering over 100 million people [4]. AI as a Core Driver of Change - AI is becoming a central driver of transformation in the healthcare industry, with the government promoting "AI+" initiatives to integrate digital technology with market advantages [5][6]. Development of AI Applications - JD Health has been an early mover in AI within the internet healthcare sector, developing its medical AI model "Jingyi Qianxun," which has extensive application scenarios and partnerships with hospitals [7]. Enhancing Healthcare Services with AI - JD Health is leveraging AI to improve healthcare service efficiency, allowing AI to handle tasks traditionally performed by doctors, thus enabling them to focus on more valuable patient interactions [7]. Broader Impact of AI in Healthcare - AI is not only enhancing JD Health's service efficiency but is also reshaping the entire healthcare industry, providing significant value in resource supply and patient care [8]. Vision for the Future - JD Health aims to set a benchmark for "efficiency and warmth" in the industry through digital innovation and efficiency transformation, contributing to the evolution of China's internet healthcare sector [8].

Investment Rating - The report initiates coverage with an OUTPERFORM rating for BeiGene [2]. Core Insights - BeiGene is positioned as a leading biopharma company in China, focusing on innovative drug development and global commercialization, with a strong pipeline and significant growth potential [3][11]. - The company is expected to achieve profitability by 2025, driven by the strong performance of its core products, particularly the BTK inhibitor, Zanubrutinib, and the PD-1 inhibitor, Tislelizumab [4][20]. Summary by Sections 1. Innovative Product Globalization - BeiGene has established a robust global presence with over 60 clinical projects and 17 commercialized products, including Zanubrutinib and Tislelizumab, which have been launched in multiple regions [3][11]. - The company aims to become the first biopharma in China to achieve recurring profitability by 2025, supported by its innovative product pipeline and global commercialization capabilities [11][20]. 2. Leadership in Hematology - The combination of BTK inhibitors, BCL-2 inhibitors, and BTK CDAC is expected to solidify BeiGene's leadership in hematological malignancies [5][27]. - Zanubrutinib is projected to double its revenue to $2.6 billion in 2024, further strengthening its market position in the U.S. hematology market [4][20]. 3. Pipeline Development - BeiGene's pipeline focuses on hematological and solid tumors, with several molecules showing best-in-class potential, including Sonrotoclax and BGB-16673 [27]. - The company has a rich pipeline with over 10 early-stage projects expected to report proof-of-concept data in 2025, enhancing its growth prospects [6][27]. 4. Financial Projections and Valuation - Revenue projections for FY25-27 are $5 billion, $6 billion, and $6.7 billion, respectively, with a CAGR of 21% [7]. - The target price is set at HK$182.35, based on a discounted cash flow model with a WACC of 9% and a perpetual growth rate of 4% [7].

Core Viewpoint - The article discusses the declining birth rates in China and its implications for the education sector, particularly focusing on the decreasing number of students in kindergartens and primary schools, while also highlighting the rise of domestic erectile dysfunction (ED) medications that challenge the monopoly of foreign brands [1][2][3][4]. Summary by Sections Declining Birth Rates - The number of kindergarten students in China decreased by 5.35 million in 2023 and is projected to decrease by another 5.09 million in 2024, marking a four-year decline trend [1]. - The number of primary school students is also declining, with a reduction of 2.52 million in 2024 [2]. - The primary reason for these declines is the continuous drop in newborn population, which may worsen in 2025 due to declining marriage rates [3]. Factors Influencing Birth Rates - The decline in birth rates is attributed to various factors, including social and economic changes, housing price pressures, and a decrease in fertility rates [3]. - A report from the World Health Organization indicates that approximately 17.5% of adults globally are affected by infertility, a trend that is increasing [3]. Rise of Domestic ED Medications - Erectile dysfunction (ED) is identified as a significant factor affecting birth rates, with 38.17% of men under 60 in China suffering from this condition [4]. - The high prices of traditional foreign ED medications have limited access for many patients, but domestic alternatives like "Guai Ai" are emerging, offering similar quality at significantly lower prices [4][6]. Market Dynamics and Competition - The introduction of "Guai Ai" represents a pivotal moment in the ED medication market, with prices ranging from 3 to 6 yuan per pill, compared to 68 yuan for foreign brands [12][13]. - The success of "Guai Ai" is attributed to its affordability and effectiveness, leading to over 100 million units sold within two years of launch [13][14]. Production and Technological Advancements - China is the largest producer of active pharmaceutical ingredients, which has helped lower the costs of raw materials for domestic drug manufacturers [16]. - The automation and digitalization of production processes in Chinese pharmaceutical companies have further enhanced efficiency and reduced costs [17][18]. Changing Sales Channels - The traditional barriers to purchasing ED medications are being dismantled through online platforms and services, allowing for easier access to these products [18]. - The integration of online consultations and delivery services has created a comprehensive ecosystem for ED treatment, shifting the market dynamics from price competition to a focus on service and accessibility [18].

Investment Rating - The report initiates coverage with an OUTPERFORM rating for BeiGene [2]. Core Views - BeiGene is positioned as a leading innovator in China's biopharmaceutical sector, with a strong focus on oncology treatments and a robust pipeline of over 60 clinical projects globally [3][11]. - The company is expected to achieve profitability by 2025, driven by significant revenue growth from its core products, particularly the BTK inhibitor, Zanubrutinib, which is projected to double its revenue in 2024 [4][20]. - BeiGene's global commercialization capabilities and a well-established management team are key competitive advantages that will support its growth trajectory [12][29]. Summary by Sections 1. Innovative Product Globalization - BeiGene has a diverse product pipeline and aims to become the first biopharma company to achieve consistent profitability [11]. - The company has 17 commercialized products, including Zanubrutinib and Tislelizumab, with strong sales performance in the US and Europe [20]. - Revenue for 2024 is projected at $3.81 billion, a 55% increase year-over-year, with significant contributions from the US market [20]. 2. Leadership in Hematology - The combination of BTK inhibitors and BCL-2 inhibitors is expected to solidify BeiGene's leadership in hematological malignancies [5]. - Zanubrutinib has shown superior efficacy compared to Ibrutinib, establishing its best-in-class status [5][24]. - The company is also developing Sonratoclax, a BCL-2 inhibitor, which is anticipated to enhance its market position [5]. 3. Expansion in Solid Tumors - BeiGene is actively expanding its presence in solid tumors, with Tislelizumab gaining traction in various indications [11]. - The company is developing next-generation CDK inhibitors targeting a market exceeding $10 billion [11]. - Focus areas include lung cancer and breast cancer, with ongoing clinical trials for multiple candidates [11]. 4. Financial Projections and Valuation - Revenue forecasts for FY25-27 are $5 billion, $6 billion, and $6.7 billion, respectively, with a CAGR of 21% [7]. - The net profit is expected to turn positive by FY25, reaching $390 million by FY26 [7]. - The target price is set at HK$182.35, based on a DCF model with a WACC of 9% and a perpetual growth rate of 4% [7].

Core Viewpoint - The article discusses the disruption of established pharmaceutical monopolies, particularly focusing on the case of Viagra and the emergence of cost-effective alternatives in the Chinese market, highlighting the impact of competitive pricing and innovative business models on traditional market leaders [1][10]. Section Summaries Introduction - The launch of deepseek, a large model trained with 2048 NVIDIA H800 chips, parallels historical market disruptions, leading to significant declines in stock prices for major players like NVIDIA, suggesting a pattern of vulnerability in perceived monopolies [1]. Origin of Viagra - Viagra, developed from an unexpected discovery in the 1990s, became a commercial success with over $32 billion in sales from 1998 to 2017, establishing a strong market presence during its patent period [2][3]. Challenges to Viagra - Despite the introduction of Cialis in 2002, Viagra maintained its dominance due to similar pricing strategies among leading pharmaceutical companies, which avoided triggering price wars [5][6]. Emergence of Chinese Competitors - Following the expiration of Viagra's patent in China in 2014, local companies introduced generics at 20%-30% lower prices, leading to a significant market shift with products like "惯爱" priced at 3-6 RMB, drastically reducing patient costs [6][7]. Business Strategy of "惯爱" - The success of "惯爱" is attributed to a disruptive pricing strategy that expands market share and reduces costs through economies of scale, creating a positive feedback loop of growth and innovation [7][8]. Production and Supply Chain Advantages - China's position as the largest producer of active pharmaceutical ingredients has lowered production costs, enabling competitive pricing for domestic drugs [8][9]. Technological Advancements in Production - The automation and digitization of production processes in China have enhanced efficiency, allowing companies like "惯爱" to maintain high-quality standards while keeping prices low [9]. Reconstructing Market Dynamics - The integration of online healthcare services with pharmaceutical distribution has transformed the erectile dysfunction drug market, shifting the focus from price competition to a comprehensive service model [10].

2025 年 03 月 03 日 行业周报 看好/维持 医药 医药 礼来与 Magnet 达成近 13 亿美元分子胶合作 科伦药业（002422）：公司发布公告，公司 5%以上持股股东雅安国资 拟通过集中竞价的方式增持公司股份，拟增持金额为 5000-9900 万元，增 持价格不超过 37.60 元/股，资金来源为自有资金和股票回购专项贷款。 鱼跃医疗（002223）：公司发布公告，公司申请的自动体外除颤器（AED） 获得符合欧盟《医疗器械第 2017/745 号法规》（MDR）要求的 III 类医疗 器械 CE 认证证书，此次获批表明该产品具备欧盟市场的最新准入条件， 进一步提升了公司急救类产品在相应领域的综合竞争力。 昭衍新药（603127）：公司发布公告，公司累计通过集中竞价交易方 式回购 A 股股份 3,269,820 股，占公司总股份的 0.4363%，回购价格区间 为 13.20-18.15 元/股，使用资金总额为人民币 52,991,757.40 元（不含 交易费用）。 ◼ 走势比较 报告摘要 市场表现： 2025年3月3日，医药板块涨跌幅+0.66%，跑赢沪深300指数0.70pct， 涨跌幅 ...